 | Up a level |
Steffen, Thomas; Dietrich, Daniel; Schnider, Annelies; Kettelhack, Christoph; Huber, Olivier; Marti, Walter R; Furrer, Markus; Gloor, Beat; Schiesser, Marc; Thierstein, Sandra; Brauchli, Peter; Ruhstaller, Thomas (2019). Recurrence Patterns and Long-Term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer. Annals of surgery, 269(1), pp. 83-87. Lippincott Williams & Wilkins 10.1097/SLA.0000000000002435
Zweifel, Martin; Thürlimann, Beat; Riniker, Salome; Weder, Patrik; von Moos, Roger; Pagani, Olivia; Bigler, Martin; Rothgiesser, Karin M; Pilop, Christiane; Hawle, Hanne; Brauchli, Peter; Tapia, Coya; Schoenfeld, Wolfgang; Sessa, Cristiana (2017). Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. Endocrine Connections, 6(7), pp. 549-556. BioScientifica 10.1530/EC-17-0174
Herrmann, Evelyn; Naehrig, Diana; Sassowsky, Manfred; Bigler, Martin; Buijsen, Jeroen; Ciernik, Ilja; Zwahlen, Daniel; Pellanda, Alessandra Franzetti; Meister, Andreas; Brauchli, Peter; Berardi, Simona; Kuettel, Erika; Dufour, Jean-François; Aebersold, Daniel; Swiss Group for Clinical Cancer Research, SAKK (2017). External beam radiotherapy for unresectable hepatocellular carcinoma, an international multicenter phase I trial, SAKK 77/07 and SASL 26. Radiation oncology, 12(1), p. 12. BioMed Central 10.1186/s13014-016-0745-0
Clough-Gorr, Kerri M; Noti, Lea; Brauchli, Peter; Cathomas, Richard; Fried, Marius R.; Roberts, Gillian; Stuck, Andreas; Hitz, Felicitas; Mey, Ulrich (2013). The SAKK cancer-specific geriatric assessment (C-SGA): a pilot study of a brief tool for clinical decision-making in older cancer patients. BMC medical informatics and decision making, 13(1), p. 93. London: BioMed Central 10.1186/1472-6947-13-93
Passweg, Jakob R.; Pabst, Thomas; Blum, Sabine; Bargetzi, Mario; Li, Qiyu; Heim, Dominik; Stussi, Georg; Gregor, Michael; Leoncini, Leda; Meyer-Monard, Sandrine; Brauchli, Peter; Chalandon, Yves; Swiss Group for Clinical Cancer Research, SAKK (2013). Azacytidine for acute myeloid leukemia in elderly or frail patients: A phase II trial (SAKK 30/07). Leukemia & lymphoma, 55(1), pp. 87-91. London: Informa Healthcare 10.3109/10428194.2013.790540
Zappa, Francesco; Droege, Cornelia; Betticher, Daniel; von Moos, Roger; Bubendorf, Lukas; Ochsenbein, Adrian; Gautschi, Oliver; Oppliger Leibundgut, Elisabeth; Froesch, Patrizia; Stahel, Rolf; Hess, Thomas; Rauch, Daniel; Schmid, Petra; Mayer, Michael; Crowe, Susanne; Brauchli, Peter; Ribi, Karin; Pless, Miklos; on behalf of the Swiss Group for Clinical Cancer Research (SAKK), (2012). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05). Lung cancer, 78(3), pp. 239-44. Amsterdam: Elsevier 10.1016/S1359-6349(09)71860-9
Cathomas, Richard; Rothermundt, Christian; Klingbiel, Dirk; Bubendorf, Lukas; Jaggi, Rolf; Betticher, Daniel C; Brauchli, Peter; Cotting, Denise; Droege, Cornelia; Winterhalder, Ralph; Siciliano, Daniele; Berthold, Dominik R; Pless, Miklos; Schiess, Ralph; von Moos, Roger; Gillessen, Silke (2012). Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clinical cancer research, 18(21), pp. 6049-57. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-12-2219
Ruhstaller, Thomas; Pless, Miklos; Dietrich, Daniel; Kranzbuehler, Helmut; von Moos, Roger; Moosmann, Peter; Montemurro, Michael; Schneider, Paul M; Rauch, Daniel; Gautschi, Oliver; Mingrone, Walter; Widmer, Lucas; Inauen, Roman; Brauchli, Peter; Hess, Viviane (2011). Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). Journal of clinical oncology, 29(6), pp. 626-31. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2010.31.9715
Leupin, Nicolas; Schuller, Jan C; Solenthaler, Max; Heim, Dominik; Rovo, Alicia; Beretta, Kurt; Gregor, Michael; Bargetzi, Mario J; Brauchli, Peter; Himmelmann, Andreas; Hanselmann, Silvia; Zenhäusern, Reinhard (2010). Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02). Leukemia & lymphoma, 51(4), pp. 613-9. London: Informa Healthcare 10.3109/10428191003624231
Jost, Christian; Binek, Janek; Schuller, Jan C; Bauerfeind, Peter; Metzger, Urs; Werth, Baseli; Knuchel, Juerg; Frossard, Jean-Louis; Bertschinger, Philipp; Brauchli, Peter; Meyenberger, Christa; Ruhstaller, Thomas (2010). Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research (SAKK 75/02). Gastrointestinal endoscopy, 71(7), pp. 1114-21. New York, N.Y.: Elsevier 10.1016/j.gie.2009.12.015
Klaeser, Bernd; Nitzsche, Egbert; Schuller, Jan C; Köberle, Dieter; Widmer, Lucas; Balmer-Majno, Sabine; Hany, Thomas; Cescato-Wenger, Corinne; Brauchli, Peter; Zünd, Michael; Pestalozzi, Bernhard C; Caspar, Clemens; Albrecht, Susanne; von Moos, Roger; Ruhstaller, Thomas (2009). Limited predictive value of FDG-PET for response assessment in the preoperative treatment of esophageal cancer: results of a prospective multi-center trial (SAKK 75/02). Onkologie, 32(12), pp. 724-30. Basel: Karger 10.1159/000251842
Schuller, Jan C.; Mayer, Michael; Lanz, Doris; Hsu Schmitz, Shu-Fang; Brauchli, Peter; Leupin, Nicolas (2009). A novel diagram and complement to the CONSORT chart for presenting multimodal clinical trials. Contemporary clinical trials, 30(3), pp. 201-204. New York, N.Y.: Elsevier 10.1016/j.cct.2009.01.010
Koeberle, Dieter; Betticher, Daniel; Von Moos, Roger; Dietrich, Daniel; Brauchli, Peter; Baertschi, Daniela; Matter-Walstra, Klazien; Winterhalder, Ralph; Borner, Markus; Anchisi, Sandro; Moosmann, Peter; Kollár, Attila; Saletti, Piercarlo; Roth, Arnaud; Frueh, Martin; Kueng, Marc; Popescu, Razvan; Schacher, Sabina; Hess, Viviane and Herrmann, Richard (2013). O-0028 Bevacizumab Continuation Versus No Continuation After First-Line Chemo-Bevacizumab Therapy in Patients with Metastatic Colorectal Cancer: a Phase 3 Non-Inferiority Trial. Annals of oncology, 24(Suppl 4), iv22-iv22. Oxford University Press 10.1093/annonc/mdt201.28
Schuller, Jan C.; Brauchli, Peter; Dietrich, Daniel; Herrmann, Richard; Klingbiel, Dirk; Lerch, Stefanie; Mayer, Michael; Simcock, Mathew; Hsu Schmitz, Shu-Fang (2009). Should phase II cancer screening trials include a control arm? 30th Annual Conference of the International Society for Clinical Biostatistics, August 23-27, 2009, Prague.
